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Gerard Socie,1,2,3 Jerome Ritz,4 Paul J. Martin5Chronic graft-versus-host disease (cGVHD), a multiorgan disorder, is the leading cause of late nonrelapse
mortality (NRM) after hematopoietic stem cell transplantation (HSCT). Despite many years of experience
with this disease we are still faced with numerous challenges including (among others); lack of reliable pre-
clinical models, poor knowledge of human pathophysiology, validated diagnostic and severity criteria, and un-
predictable clinical response to first line treatment. We will review recent advances on the 3 last mentioned
unresolved areas.
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In contrast to acute graft-versus-host disease
(aGVHD), chronic GVHD (cGVHD) often presents
with clinical manifestations that resemble those of
autoimmune diseases such as scleroderma, Sjo¨gren’s
syndrome, and systemic lupus erythrematosus (SLE).
Nevertheless, relatively little is known about the im-
mune mechanisms that lead to the development of
cGVHD and how these might be similar or different
than conventional autoimmune diseases. Despite hav-
ing features of autoimmunity, cGVHD only occurs in
the setting of allogeneic hematopoietic stem cell trans-
plantation (HSCT). Moreover, both aGVHD and
cGVHD can be prevented by depletion of T cells
from the donor graft. Thus, donor T cells responding
to allogeneic antigens in the recipient must play a cen-
tral role in the development of cGVHD, but the pre-
cise immunologic targets of cGVHD are not well
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6/j.bbmt.2009.10.013lead to the distinctive but highly variable clinical
features of this disease remain largely unknown.
B and T Cell Responses in cGVHD
Although donor T cells play a central role in the
development of both aGVHD and cGVHD, recent
studies have provided evidence that B cells also con-
tribute to the clinical manifestations of this disease.
In male patients who receive stem cell grafts from
female donors, proteins encoded by a small number
of genes on the Y chromosome have been shown to
be targets of both T and B cell responses. In males,
these proteins are self-antigens, and T cells specific
for these antigens are deleted during thymic differen-
tiation. Similarly, B cells specific for HY proteins are
also deleted in males. In contrast, normal females are
not exposed to these proteins and do not develop tol-
erance. When transplanted into male recipients, naive
female lymphocytes encounter these Y-encoded
proteins for the first time and respond to these pro-
teins as though they were ‘‘foreign’’ antigens [1].
Approximately one-third of known minor histocom-
patibility antigens (miHA) are derived from this small
set of genes on the Y chromosome, indicating that
peptide epitopes from these proteins are readily pro-
cessed and presented by both HLA class I and class II
molecules. These peptide epitopes are readily recog-
nized by the naı¨ve female T cell repertoire, resulting
in the clonal expansion of T cells specific for these
widely expressed target antigens [2]. T cells specific
for Y-encoded miHA are often detected in patients
with cGVHD as well as aGVHD, and the immuno-
genicity of these proteins is presumed to explain the
increased incidence of both aGVHD and cGHVD
in male patients with female stem cell donors [1].
When patients and donors are HLA matched and
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are presumed to the primary antigenic targets of
aGVHD and cGVHD, but relatively few of these epi-
topes have actually been described and further studies
are needed to identify and characterize the targets of
T cell immunity in patients with cGVHD.
Male patients who receive stem cell grafts from
female donors have provided a unique model in which
to characterize B cell responses to alloantigens after
HSCT. Whereas T cell responses are directed against
peptide epitopes presented by HLA class I and class II
molecules, antibody responses are directed against
soluble antigens. To characterize B cell responses
against miHA, we therefore tested plasma from
patients with cGVHD for IgG antibodies specifically
reactive with recombinant HY proteins by Western
blot and by ELISA [3,4]. HY antibodies were detected
in approximately 50% of male patients with female
donors compared to \10% of male patients with
male donors. HY antibodies typically develop 6 to 12
months after HSCT and are not associated with
aGVHD or other clinical variables. However, the
presence of these antibodies is significantly associated
with the development of cGVHD [4]. These findings
suggest that B cell responses to HY antigens also con-
tribute to the pathogenesis of cGVHD, but the
Y-encoded antigens that elicit this antibody response
are intracellular proteins and not expressed on the
cell membrane. It is therefore unlikely that antibodies
specific for these antigens are directly toxic to recipient
cells and the mechanisms whereby these antibodies
contribute to tissue damage remains to be elucidated.
B Cell Activating Factor (BAFF) and cGVHD
BAFF supports the differentiation and survival of
normal B cells, and elevated levels of BAFF in patients
with autoimmune diseases have been shown to pro-
mote the persistence of autoreactive B cells. Consider-
ing this important role of BAFF in B cell homeostasis,
our laboratory examined the role of BAFF in the
reconstitution of B cell immunity after HSCT. Soluble
BAFF was measured in plasma by ELISA, and initial
studies found that patients with active cGVHD had
significantly elevated levels of BAFF compared with
patients with resolved cGVHD or patients who never
developed cGVHD after transplant [5]. Prospective
monitoring of BAFF levels showed that they were
typically elevated in the first 3 months after HSCT.
In patients who reconstitute normal numbers of naı¨ve
B cells, BAFF levels return toward normal. However,
BAFF levels remain elevated in the absence of recovery
of naı¨ve B cells and persistently high levels of BAFF
promote the survival of activated CD271 B cells.
The persistence of CD271 activated B cells and high
levels of BAFF are both associated with the subsequent
development of cGVHD [6]. The observation that
donor B cells play a role in cGVHD has led to severalstudies evaluating the safety and efficacy of B cell-di-
rected therapy with rituximab (anti-CD20) in patients
with steroid refractory cGVHD [7]. Several reports
have established the efficacy of this treatment, but
few complete responses (CR) are achieved with rituxi-
mab therapy and other B cell-directed approaches may
be more effective [8]. In this context, anti-BAFF agents
represent an alternative approach because reduction in
the levels of BAFF might provide a more specific and
less toxic way of reducing the chronic stimulation
and activation of reconstituting donor B cells and
suppressing secretion of alloreactive and potentially
autoreactive antibodies.
CD41 Regulatory T Cells in cGVHD
Similar to autoimmune diseases, both T and B cell
responses appear to play a role in the pathogenesis of
cGVHD, suggesting that this reflects a general loss
of tolerance including abnormalities in the function
of CD41 regulatory T cells (Tregs). Studies in mice
have clearly shown that Tregs are capable of suppress-
ing GVHD, and that deficiency of Tregs can lead to
increased severity of GVHD. Our previous analysis
of patients with cGVHD showed that these patients
had a relative deficiency of Tregs compared to patients
without GVHD [9]. To understand the mechanisms
responsible for this deficiency of Tregs we compared
the reconstitution of Tregs with conventional CD41
T cells (Tcons) in the first year after transplant. During
this period, thymic generation of Tregs was signi-
ficantly impaired compared with Tcons, but Tregs
exhibited higher levels of endogenous proliferation.
Importantly, overall Tregs reconstitution remained
low because this high level of proliferation was coun-
terbalanced by a greater susceptibility to apoptosis.
This homeostatic imbalance led to depletion of the
Treg population in peripheral blood and was associ-
ated with a high incidence and severity of cGVHD.
In summary, recent studies of immune reconstitu-
tion after allogeneic HSCT have provided several
novel insights into the mechanisms that lead to the de-
velopment of cGVHD. As clinical methods to modu-
late T, B, and Treg function become available, these
approaches can be applied in a rationale way to both
deplete alloreactive T and B cell populations and to
establish a normal level of peripheral tolerance [10].
These new approaches may provide more effective
treatment or strategies to prevent the development of
this important complication of allogeneic HSCT.CURRENT ISSUES IN DISEASE DEFINITION
AND SEVERITY (G. SOCIE)
Disease Definition
It has been known for many years that, although
the disease usually manifests itself more than 100 days
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More importantly, clinical syndromes with features
of typical aGVHD are increasingly recognized beyond
100 days after HSCT especially in recent years with
the development of reduced-intensity conditioning
(RIC) regimens [11]. In addition, patients with
aGVHD may progress to develop cGVHD with symp-
toms of both aGVHD and cGVHD. For many years,
we have used a grading system, developed by the Seattle
group [12], of limited versus extensive GVHD. This
study was designed to identify patients needing sys-
temic immune suppression, but does not capture the
severity of individual organ involvement. Although
other grading schemes have been proposed (reviewed
in [13]) to predict survival following cGVHD, all lack
consistent scoring and assessment of each organ in-
volved to determine the overall severity of the disease.
Recognizing these limitations, a group of experts lead
by Dr. Pavletic at the NIH met in 2004 for a consensus
conference on cGVHD. Because all participants
agreed that it was urgently necessary to get rid of the
formal definition of cGVHD (any GVHD beyond
day 100), the diagnosis and staging working group of
the NIH Consensus Development Project on cGVHD
[14] proposed standard criteria for diagnosis (Table 1),
organ scoring, and global assessment of cGVHD sever-
ity (see reference for the details on how to score organ
severity and to assign a severity grade).Usefulness of the NIH Criteria?
As of today, 5 groups worldwide have attempted to
study patients who developed GVHD more than 100
days after allogeneic transplantation and to reclassify
cGVHD using the NIH criteria. Two early studies,
1 by the Nashville group involving 110 patients [15],
and another 1 from the Minneapolis group involving
54 patients [16], provided initial estimates. Classifica-
tions in both studies were late aGVHD (36% and
15%), overlap syndrome (26% and 28%), and classic
cGVHD (37% and 57%) (estimates from [15] and
[16], respectively). Then Cho et al [17] studied 211
patients. Classifications were: late aGVHD (21%),
overlap syndrome (30%), and classic cGVHD 49%).Table 1. NIH Criteria for aGVHD and cGVHD
Category
Time of
symptoms
Presence of
aGVHD Features
Presence of
cGVHD Features
aGVHD
Classic acute #100 D Yes No
Persistent >100 D Yes No
Recurrent
Late onset acute
cGVHD
Classic chronic no time limits No Yes
Overlap syndrome no time limits Yes Yes
cGVHD indicates chronic graft-versus-host disease; aGVHD, acute
graft-versus-host disease.Classic cGVHD and overlap syndrome patients (n 5
167) were graded using both the revised Seattle criteria
and NIH global scoring. This large study addressed
the critical point of what’s left with chronic GVHD
using the stringent NIH disease criteria. Despite not
being based on same patient number, and including
different patient, disease, and transplant characteris-
tics, one can thus reasonably assume that around
20% of patients formally classified as cGVHD using
the Seattle day 100 landmark could, in fact, be consid-
ered as having features of an acute inflammatory dis-
ease. Most recently, the Seattle group addressed this
issue in studying 740 patients who underwent HSCT
after myeloablative (MA) conditioning and diagnosed
with historically defined cGVHD. The presence or
absence of NIH criteria for cGVHD showed no statis-
tically significant association with survival, risks of
nonrelapse mortality (NRM), or recurrent malig-
nancy, or the duration of systemic treatment. Anteced-
ent late aGVHD was associated with an increased risk
of NRM and prolonged treatment among patients
with NIH cGVHD. Authors concluded that these
results support the consensus recommendation that,
with appropriate stratification, clinical trials can in-
clude patients with late aGVHD as well as those with
NIH cGVHD [18]. In an unpublished study, we at
the Hospital St Louis retrospectively reviewed 116
consecutive patients undergoing an SCT for hemato-
logic malignancy after RIC. After a median follow-
up of 18 months, a total of 67 patients (58%) developed
cGVHD according to the Seattle day 100 landmark
criteria. When using NIH consensus criteria, 55
(47%) developed cGVHD (including 43 [53%] with
classic cGVHD and 8 [10%] with overlap syndrome).
Patients reclassified included; 3 patients with late-onset
aGVHD, 19 with recurrent, and 8 with persistent
aGVHD. The cumulative incidence of cGVHD at 36
months was 64% (95% confidence interval [CI];
53%-73%) when using Seattle criteria compared to
56% (95% CI; 45%-67%) with NIH cGVHD criteria.
Have those studies a purely semantic interest? I do
not so believe. This means that all estimates currently
published in the literature underestimate aGVHD
incidence and overestimate that of cGVHD. This is
not of major importance if you are aware of this caveat;
however, it is of importance if you want to use these
incidences to calculate the power of a clinical trial or
if you want to search for a statistical link between either
acute or cGVHD with relapse (graft-versus-leukemia
[GVL] effect), for example.Current Issues in Using the NIH Criteria
Ongoing unresolved issues include: (1) difference
(if any) in GVHD-specific survival between in patient
with late aGVHD compared to those with classical
cGVHD or with the overlap syndrome? (2) Which
Table 2. Randomized Clinical Trials in cGVHD
Author Arms Compared Double Blind Results
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tion of immunosuppressive therapy? (3) Which classi-
fication will be a better discriminator of disease severity?Sullivan [20] Prednisone ± Azathioprine Yes Decreased survival
Koc [21] Prednisone ± cyclosporine No Limited benefit
Koc [22] Cyclosporine/Prednisone
± thalidomide
Yes Toxicity
Arora [23] Cyclosporine/Prednisone
± thalidomide
No No benefit
Martin [24] Prednisone
± mycophenolate mofetil
Yes No benefit
cGVHD indicates chronic graft-versus-host disease.INITIALTREATMENTOF CHRONIC GVHD
(P.J. MARTIN)
In general, systemic immunosuppressive treatment
is not needed for patients with mild manifestations of
cGVHD involving a single organ, unless adverse risk
factors are present. Risk factors associated with an in-
creased risk of NRM include platelet count\100,000
at onset, treatment with prednisone at onset, anteced-
ent aGVHD, and hyperbilirubinemia at onset. Sys-
temic treatment is needed for patients with more
severe manifestations, especially when multiple sites
are involved. The treatments studied during the past
2 decades, have not demonstrably accelerated the res-
olution of cGVHD [19]. Survival at 5 years among pa-
tients with ‘‘standard-risk’’ cGVHD is approximately
70%, and survival among those with ‘‘high-risk’’ fea-
tures of thrombocytopenia or antecedent aGVHD is
approximately 50%.
Need for Glucocorticoid-Sparing Regimens
in Treatment of cGVHD
Systemic glucocorticoids have long served as the
mainstay of treatment for cGVHD. Initial doses of
1.0 mg/kg per day have been recommended, followed
by tapering over a period of several months as allowed
by improvement in disease manifestations. Long-term
treatment with high-dose prednisone is associated with
a high risk of complications and considerable morbid-
ity. Some complications can be ameliorated by every
other day administration of prednisone as opposed to
daily administration. Effective glucocorticoid-sparing
treatments would be of enormous benefit for patients
with cGVHD, provided that the reduction in glucocor-
ticoid-related side effects offsets any adverse effects of
the treatment used to reduce the reliance on glucocor-
ticoids. Benefits of effective initial treatment with
glucocorticoid-sparing agents would be expected to
include earlier discontinuation of immunosuppressive
therapy, a reduced incidence of complications related
to treatment with prednisone, a lower probability of
secondary therapy, and a lower probability of death
from causes other than recurrent malignancy.
Paucity of Randomized Trials for Treatment
of cGVHD
Only 5 randomized trials [20–24] for systemic
treatment of cGVHD have ever been reported
(Table 2), and the principal clinical trials registration
site in the United States currently lists only 7 phase
II studies that are actively recruiting patients for sys-
temic treatment of cGVHD. The historic paucity ofphase III clinical trials for treatment of cGVHD re-
flects the difficulty of designing and conducting such
studies. Virtually all previous treatment studies of
cGVHD have been conducted with the use of agents
that have been previously approved for other indica-
tions. Academic investigators have found it very diffi-
cult to attract the interest of industry partners,
because cGVHD is an orphan indication with no es-
tablished template for an approval path at the FDA.
Identification of validated shorter term endpoints is
critically important to overcome these obstacles and
to attract the interest of industry partners toward in-
vesting in clinical trials related to cGVHD. Successful
identification of validated short-term endpoints could
create future opportunities to test novel agents that
have not already been approved for other indications.
Lack of Validated Endpoints for Clinical Trial
Clinical trials in patients with cGVHD have been
hampered by the lack of validated scales based on ob-
jective measurements that can be used to assess re-
sponse and outcome after treatment, although some
progress toward this goal has been made [25–27].
Many clinical trials have used ‘‘clinical improvement,’’
partial response (PR), or CR as endpoints, often at un-
specified times after enrollment. As a more rigorous
endpoint, some trials have used time to discontinua-
tion of all immunosuppressive treatment as an indica-
tor of cure, but ascertainment of this endpoint requires
lengthy follow-up. Survival and mortality from causes
other than recurrent malignancy have been used as
unequivocal objective endpoints in clinical trials to
measure the efficacy of treatment for cGVHD. None-
theless, the interpretation of single-arm trials remains
difficult because of potential selection bias. The key
question is whether any shorter term endpoint could
be used as a valid surrogate for longer term cure of
the disease. Such endpoints would make it much easier
to evaluate the merits of new approaches for treatment
of cGVHD by shortening the timeline needed to assess
outcomes and to identify promising new approaches.
Challenges for the Future
In a recently completed multicenter double-blinded
trial [24], we found that the addition of mycophenolate
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men used for treatment of cGVHD did not accelerate
the resolution of cGVHD and withdrawal of systemic
immunosuppressive treatment. We considered several
explanations that might have accounted for the inability
of MMF to produce favorable results, including an over-
stringent primary endpoint, suboptimal dosing of
MMF, and inappropriate pacing of steroid withdrawal.
Although data were limited, careful examination of re-
sults did not support any of these potential explanations.
Hence, we concluded that MMF did not provide any
overall benefit as a component in the initial treatment
of cGVHD. By some measures, trends suggested that
MMF may cause harm when added to conventional sys-
temic immunosuppressive treatment for cGVHD.
This experience raises some major points for con-
sideration by investigators interested in treatment of
cGVHD. First, clinical trials should use randomized
designs whenever possible. Numerous case-series re-
ports and uncontrolled phase II studies suggested en-
couraging results with the use of MMF for treatment
of steroid-refractory cGVHD, but our results with
the use of MMF for initial treatment of cGVHD do
not support the use of MMF for this indication. Sec-
ond, despite concerted efforts to facilitate participa-
tion by physicians and patients at 15 centers, it took
4 years to enroll 157 patients in our study. Progress
would be enhanced if physicians could more readily ac-
knowledge the limitations of previous studies, thereby
maintaining appropriate clinical equipoise with re-
spect to unproved treatments. Third, clinical trials
should involve collaborations between investigators
and industry so that trials can use double-blinded
designs to produce robust results. Blinding in cGVHD
trials is especially important when objective measures
remain difficult to document and when clinical
endpoints unavoidably involve subjective judgment.
Finally, improved understanding of the pathophysiol-
ogy of cGVHD will be needed to develop more effec-
tive approaches for treatment. A challenge for the
future will be the discovery of approaches that can tar-
get the cause of cGVHD while permitting reconstitu-
tion of immune defenses against pathogens and
preserving immunologic effects of donor cells against
malignant cells in the recipient.
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